AR and prostate carcinoma: First, we asked if KCZ or KCZ-7 inhibited tGLI1-positive breast cancer through androgen receptor antagonism, since KCZ is known to inhibit the androgen receptor and has shown clinical efficacy as a second-line therapy for castration-resistant prostate cancer [28].